Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-96. doi:10.1200/JCO.2010.33.2312
Petrovics G, Li H, Stümpel T, et al. A novel genomic alteration of LSAMP associates with aggressive prostate cancer in African American men. EBioMedicine. 2015;2(12):1957-64. doi:10.1016/j.ebiom.2015.10.028
Ottoboni L, Keenan BT, Tamayo P, et al. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012;4(153):153ra131. doi:10.1126/scitranslmed.3004186
Groner AC, Cato L, de Tribolet-Hardy J, et al. TRIM24 Is an Oncogenic Transcriptional Activator in Prostate Cancer. Cancer Cell. 2016;29(6):846-58. doi:10.1016/j.ccell.2016.04.012
Van Allen EM, Pomerantz M. Moving toward personalized medicine in castration-resistant prostate cancer. Urol Clin North Am. 2012;39(4):483-90. doi:10.1016/j.ucl.2012.07.005
Stieglitz E, Taylor-Weiner AN, Chang TY, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47(11):1326-1333. doi:10.1038/ng.3400
Hoshida Y, Villanueva A, Sangiovanni A, et al. Prognostic gene expression signature for patients with hepatitis C-related early-stage cirrhosis. Gastroenterology. 2013;144(5):1024-30. doi:10.1053/j.gastro.2013.01.021
Brastianos PK, Carter SL, Santagata S, et al. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164-77. doi:10.1158/2159-8290.CD-15-0369
Penney KL, Stampfer MJ, Jahn JL, et al. Gleason grade progression is uncommon. Cancer Res. 2013;73(16):5163-8. doi:10.1158/0008-5472.CAN-13-0427
Canter RG, Penney J, Tsai LH. The road to restoring neural circuits for the treatment of Alzheimer’s disease. Nature. 2016;539(7628):187-196. doi:10.1038/nature20412